Zkusit zdarma
Immunovant, Inc.

Immunovant, Inc.

IMVT
Cena:
$ 34.15
+0.02 (0.06%)
Valuace
70
Růst
0
Zdraví
75
Souhrn Finanční data Pro investory Předpovědi Zprávy Dividendy Zisky Návštěvnost webu Akcionáři
Souhrn
Finanční data
Pro investory
Předpovědi
Zprávy
Dividendy
Zisky
Návštěvnost webu
Akcionáři

Zprávy

Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí
Roivant: Immunovant's Rheumatoid Arthritis Win Validates The Buy

Roivant: Immunovant's Rheumatoid Arthritis Win Validates The Buy

13:09 21-05-2026

Roivant (ROIV) remains a Buy as its unique 'vant' structure rapidly advances and monetizes blockbust...

These Analysts Increase Their Forecasts On Immunovant After Q4 Results

These Analysts Increase Their Forecasts On Immunovant After Q4 Results

12:07 21-05-2026

Immunovant Inc (NASDAQ:IMVT) on Wednesday posted a wider fourth‑quarter loss than analysts expecte...

IMVT's Q4 Loss Wider Than Expected, Stock Up 35% on Strong Study Data

IMVT's Q4 Loss Wider Than Expected, Stock Up 35% on Strong Study Data

10:20 21-05-2026

Immunovant stock jumps 35% as strong early IMVT-1402 data in rheumatoid arthritis boosts confidence ...

Immunovant Stock Surges Despite Disappointing Earnings Miss

Immunovant Stock Surges Despite Disappointing Earnings Miss

13:09 20-05-2026

Immunovant Inc (NASDAQ:IMVT) shares are trading higher on Wednesday even though the company posted a...

Immunovant Q4 Earnings Call Highlights

Immunovant Q4 Earnings Call Highlights

10:08 20-05-2026

Roivant executives used the company's fourth-quarter and fiscal-year earnings call to highlight new ...

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026

7:00 20-05-2026

DURHAM, N.C., May 20, 2026 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage imm...

Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026

Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026

16:05 11-05-2026

DURHAM, N.C., May 11, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it ...

Immunovant (NASDAQ:IMVT) CTO Sells $81,573.48 in Stock

Immunovant (NASDAQ:IMVT) CTO Sells $81,573.48 in Stock

5:02 27-04-2026

Immunovant, Inc. (NASDAQ: IMVT - Get Free Report) CTO Jay Stout sold 2,754 shares of Immunovant stoc...

IMVT Stock Falls 2.4% as Batoclimab Misses Late-Stage Study Endpoints

IMVT Stock Falls 2.4% as Batoclimab Misses Late-Stage Study Endpoints

14:10 06-04-2026

Immunovant slips 2.4% after batoclimab misses key phase III endpoints in thyroid eye disease trials,...

Immunovant Batoclimab Flops in Phase 3 TED as Roivant Expands Brepocitinib Into LPP

Immunovant Batoclimab Flops in Phase 3 TED as Roivant Expands Brepocitinib Into LPP

1:05 04-04-2026

Roivant Sciences and Priovant Therapeutics executives outlined an expansion of the brepocitinib deve...

Immunovant, Inc. (IMVT) Discusses Brepocitinib Program Expansion and Batoclimab Phase III Data Update Transcript

Immunovant, Inc. (IMVT) Discusses Brepocitinib Program Expansion and Batoclimab Phase III Data Update Transcript

16:32 02-04-2026

Immunovant, Inc. (IMVT) Discusses Brepocitinib Program Expansion and Batoclimab Phase III Data Updat...

Immunovant's treatment for eye disease fails late-stage trial

Immunovant's treatment for eye disease fails late-stage trial

5:06 02-04-2026

Immunovant ​said on ‌Thursday ​that ​its therapy ⁠to ​treat a ​type of ​eye ​disea...

Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)

Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)

5:00 02-04-2026

Lichen planopilaris (LPP) is a highly morbid inflammatory scalp disorder that causes generally irrev...

A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you?

A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you?

15:39 15-03-2026

Logos added 1.1 million shares of Immunovant last quarter, a purchase estimated at about $24.5 milli...

Immunovant Stock Up 30% as Investor Trims Stake by $3 Million, But Here's Why It Still Seems Bullish

Immunovant Stock Up 30% as Investor Trims Stake by $3 Million, But Here's Why It Still Seems Bullish

12:48 11-03-2026

Alpine Global Management sold 128,039 shares of Immunovant in the fourth quarter; the estimated tran...

Immunovant Stock Surges 17% in 3 Months: What's Driving It?

Immunovant Stock Surges 17% in 3 Months: What's Driving It?

13:41 05-03-2026

IMVT gains 17% in three months as IMVT-1402 advances across autoimmune trials, with multiple data re...

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)

10:48 17-02-2026

NEW YORK, Feb. 17, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating ...

Immunovant (NASDAQ:IMVT) Hits New 12-Month High After Strong Earnings

Immunovant (NASDAQ:IMVT) Hits New 12-Month High After Strong Earnings

1:16 10-02-2026

Immunovant, Inc. (NASDAQ: IMVT - Get Free Report)'s share price hit a new 52-week high during mid-da...

IMVT Posts Narrower-Than-Expected Q3 Loss, Pipeline in Focus

IMVT Posts Narrower-Than-Expected Q3 Loss, Pipeline in Focus

12:45 09-02-2026

Immunovant beats third-quarter estimates, raises $550M to fund IMVT-1402 through launch and advances...

Immunovant, Inc. (IMVT) Q3 2026 Earnings Call Transcript

Immunovant, Inc. (IMVT) Q3 2026 Earnings Call Transcript

13:24 06-02-2026

Immunovant, Inc. (IMVT) Q3 2026 Earnings Call Transcript...

close

IMMUNOVANT PROVIDES CORPORATE UPDATES AND REPORTS FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED DECEMBER 31, 2025

06-02-2026
DURHAM, N.C., FEB. 06, 2026 (GLOBE NEWSWIRE) -- IMMUNOVANT (NASDAQ: IMVT), A CLINICAL-STAGE IMMUNOLO...
Více zde

IMMUNOVANT TO REPORT FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED DECEMBER 31, 2025, AND PROVIDE BUSINESS UPDATE ON FRIDAY, FEBRUARY 6, 2026

23-01-2026
DURHAM, N.C. AND NEW YORK, JAN. 23, 2026 (GLOBE NEWSWIRE) -- IMMUNOVANT (NASDAQ: IMVT) TODAY ANNOUNC...
Více zde

SHAREHOLDER ALERT: PURCELL & LEFKOWITZ LLP ANNOUNCES SHAREHOLDER INVESTIGATION OF IMMUNOVANT, INC. (NASDAQ: IMVT)

05-01-2026
NEW YORK, JAN. 5, 2026 /PRNEWSWIRE/ -- PURCELL & LEFKOWITZ LLP ANNOUNCES THAT IT IS INVESTIGATING IM...
Více zde

IMMUNOVANT ANNOUNCES PRICING OF $550 MILLION COMMON STOCK FINANCING

11-12-2025
NEW YORK, DEC. 11, 2025 (GLOBE NEWSWIRE) -- IMMUNOVANT, INC. (NASDAQ: IMVT), A CLINICAL-STAGE IMMUNO...
Více zde

IMMUNOVANT PROVIDES CORPORATE UPDATES AND REPORTS FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED SEPTEMBER 30, 2025

10-11-2025
STUDY IN UNCONTROLLED GRAVES' DISEASE (GD) PATIENTS TREATED FOR 24 WEEKS SHOWED FIRST-EVER POTENTIAL...
Více zde

IMMUNOVANT TO REPORT FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED SEPTEMBER 30, 2025, AND PROVIDE BUSINESS UPDATE ON MONDAY, NOVEMBER 10, 2025

27-10-2025
NEW YORK, OCT. 27, 2025 (GLOBE NEWSWIRE) -- IMMUNOVANT (NASDAQ: IMVT) TODAY ANNOUNCED THAT IT WILL R...
Více zde

ROIVANT UNVEILS DURABILITY AND TREATMENT-FREE SIX-MONTH REMISSION DATA WITH POTENTIAL TO CHANGE TREATMENT PARADIGM FOR UNCONTROLLED GRAVES' DISEASE PATIENTS

03-09-2025
NEW YORK, SEPT. 03, 2025 (GLOBE NEWSWIRE) -- IMMUNOVANT, INC. (NASDAQ: IMVT), A CLINICAL-STAGE IMMUN...
Více zde

IMMUNOVANT UNVEILS DURABILITY AND TREATMENT-FREE SIX-MONTH REMISSION DATA WITH POTENTIAL TO CHANGE TREATMENT PARADIGM FOR UNCONTROLLED GRAVES' DISEASE PATIENTS

03-09-2025
NEW YORK, SEPT. 03, 2025 (GLOBE NEWSWIRE) -- IMMUNOVANT, INC. (NASDAQ: IMVT), A CLINICAL-STAGE IMMUN...
Více zde

IMVT INVESTORS HAVE OPPORTUNITY TO JOIN IMMUNOVANT, INC. FRAUD INVESTIGATION WITH THE SCHALL LAW FIRM

27-08-2025
LOS ANGELES--(BUSINESS WIRE)---- $IMVT--IMVT INVESTORS HAVE OPPORTUNITY TO JOIN IMMUNOVANT, INC. FRA...
Více zde

IMMUNOVANT PROVIDES CORPORATE UPDATES AND REPORTS FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2025

11-08-2025
NEW YORK, AUG. 11, 2025 (GLOBE NEWSWIRE) -- IMMUNOVANT, INC. (NASDAQ: IMVT), A CLINICAL-STAGE IMMUNO...
Více zde

IMMUNOVANT PROVIDES CORPORATE UPDATES AND REPORTS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FISCAL YEAR ENDED MARCH 31, 2025

29-05-2025
IMMUNOVANT'S NEW MANAGEMENT TEAM IS FOCUSED ON RAPID CLINICAL EXECUTION FOR THE SIX ANNOUNCED INDICA...
Více zde

IMVT INVESTIGATION ALERT: ROBBINS GELLER RUDMAN & DOWD LLP ANNOUNCES INVESTIGATION INTO A PRIVATE PLACEMENT TRANSACTION BY IMMUNOVANT, INC. AND ENCOURAGES INVESTORS TO CONTACT THE FIRM

21-05-2025
SAN DIEGO--(BUSINESS WIRE)--ROBBINS GELLER RUDMAN & DOWD LLP ANNOUNCES AN INVESTIGATION INTO POTENTI...
Více zde

IMMUNOVANT ANNOUNCES NEXT PHASE OF GROWTH WITH ROIVANT INCLUDING CHANGES TO ITS LEADERSHIP TEAM AND ADDITIONAL INDICATIONS SJÖGREN'S DISEASE (SJD) AND CUTANEOUS LUPUS ERYTHEMATOSUS (CLE) FOR IMVT-1402

21-04-2025
NEW YORK, APRIL 21, 2025 (GLOBE NEWSWIRE) --  IMMUNOVANT, INC. (NASDAQ: IMVT), A CLINICAL-STAGE ...
Více zde

SHAREHOLDER ALERT: PURCELL & LEFKOWITZ LLP ANNOUNCES SHAREHOLDER INVESTIGATION OF IMMUNOVANT, INC. (NASDAQ: IMVT)

19-03-2025
NEW YORK , MARCH 19, 2025 /PRNEWSWIRE/ -- PURCELL & LEFKOWITZ LLP ANNOUNCES THAT IT IS INVESTIGATIN...
Více zde

IMMUNOVANT ANNOUNCES POSITIVE RESULTS FOR BATOCLIMAB MYASTHENIA GRAVIS (MG) AND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) STUDIES

19-03-2025
NEW YORK, MARCH 19, 2025 (GLOBE NEWSWIRE) -- IMMUNOVANT, INC. (NASDAQ: IMVT), A CLINICAL-STAGE IMMUN...
Více zde

IMMUNOVANT TO HOST INVESTOR WEBCAST AT 8:00 AM ET ON WEDNESDAY, MARCH 19 TO REVIEW RESULTS FROM BATOCLIMAB MYASTHENIA GRAVIS (MG) AND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) PROGRAMS

18-03-2025
NEW YORK, MARCH 18, 2025 (GLOBE NEWSWIRE) -- IMMUNOVANT, INC. (NASDAQ: IMVT), A CLINICAL-STAGE IMMUN...
Více zde

IMMUNOVANT REPORTS FINANCIAL RESULTS FOR THE QUARTER ENDED DECEMBER 31, 2024

06-02-2025
NEW YORK, FEB. 06, 2025 (GLOBE NEWSWIRE) -- IMMUNOVANT, INC. (NASDAQ: IMVT), A CLINICAL-STAGE IMMUNO...
Více zde

KUEHN LAW ENCOURAGES INVESTORS OF IMMUNOVANT, INC. TO CONTACT LAW FIRM

24-01-2025
NEW YORK , JAN. 24, 2025 /PRNEWSWIRE/ -- KUEHN LAW, PLLC, A SHAREHOLDER LITIGATION LAW FIRM, IS INVE...
Více zde

FCRN INHIBITOR MARKET SIZE, TARGET POPULATION, COMPETITIVE LANDSCAPE & FORECAST TO 2034 - IMMUNOVANT ADVANCES FCRN INHIBITOR PIPELINE WITH PROMISING RESULTS AND FDA GREEN LIGHT FOR PIVOTAL TRIAL

11-12-2024
PRESENTS CURRENT TREATMENT PRACTICES, EMERGING DRUGS, MARKET SHARE OF INDIVIDUAL THERAPIES, AND FCRN...
Více zde

IMMUNOVANT PROVIDES DEVELOPMENT UPDATES AND REPORTS FINANCIAL RESULTS FOR THE QUARTER ENDED SEPTEMBER 30, 2024

07-11-2024
NEW YORK, NOV. 07, 2024 (GLOBE NEWSWIRE) -- IMMUNOVANT, INC. (NASDAQ: IMVT), A CLINICAL-STAGE IMMUNO...
Více zde

IMMUNOVANT ANNOUNCES ORAL PRESENTATION OF LATE BREAKING ABSTRACT FOR PHASE 2 GRAVES' DISEASE CLINICAL DATA AT THE 2024 AMERICAN THYROID ASSOCIATION (ATA) ANNUAL MEETING

29-10-2024
NEW YORK, OCT. 29, 2024 (GLOBE NEWSWIRE) -- IMMUNOVANT, INC. (NASDAQ: IMVT), A CLINICAL-STAGE IMMUNO...
Více zde

ROIVANT PROVIDES UPDATE ON GRAVES' DISEASE DEVELOPMENT PROGRAM

09-09-2024
NEW YORK, SEPT. 09, 2024 (GLOBE NEWSWIRE) -- IMMUNOVANT, INC. (NASDAQ: IMVT), A CLINICAL-STAGE IMMUN...
Více zde

IMMUNOVANT PROVIDES UPDATE ON GRAVES' DISEASE DEVELOPMENT PROGRAM

09-09-2024
NEW YORK, SEPT. 09, 2024 (GLOBE NEWSWIRE) -- IMMUNOVANT, INC. (NASDAQ: IMVT), A CLINICAL-STAGE IMMU...
Více zde

IMMUNOVANT PROVIDES CORPORATE UPDATES AND REPORTS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FISCAL YEAR ENDED MARCH 31, 2024

29-05-2024
NEW YORK, MAY 29, 2024 (GLOBE NEWSWIRE) -- IMMUNOVANT, INC. (NASDAQ: IMVT), A CLINICAL-STAGE IMMUNOL...
Více zde

IMMUNOVANT AWARDED U.S. PATENT FOR IMVT-1402

12-03-2024
NEW YORK, MARCH 12, 2024 (GLOBE NEWSWIRE) -- IMMUNOVANT, INC. (NASDAQ: IMVT), A CLINICAL-STAGE IMMUN...
Více zde

IMMUNOVANT REPORTS FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATES FOR THE QUARTER ENDED DECEMBER 31, 2023

12-02-2024
NEW YORK, FEB. 12, 2024 (GLOBE NEWSWIRE) -- IMMUNOVANT, INC. (NASDAQ: IMVT), A CLINICAL-STAGE IMMUNO...
Více zde

IMMUNOVANT TO PRESENT AT THE 42ND ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

03-01-2024
NEW YORK, JAN. 03, 2024 (GLOBE NEWSWIRE) -- IMMUNOVANT, INC. (NASDAQ: IMVT), A CLINICAL-STAGE IMMUNO...
Více zde

IMMUNOVANT REPORTS POSITIVE INITIAL PHASE 2 RESULTS FOR BATOCLIMAB IN GRAVES' DISEASE

20-12-2023
NEW YORK, DEC. 20, 2023 (GLOBE NEWSWIRE) -- IMMUNOVANT, INC. (NASDAQ: IMVT), A CLINICAL-STAGE IMMUNO...
Více zde

IMMUNOVANT ANNOUNCES POSITIVE IMVT-1402 INITIAL 600 MG MAD RESULTS THAT CONFIRM BEST-IN-CLASS POTENTIAL

28-11-2023
NEW YORK, NOV. 28, 2023 (GLOBE NEWSWIRE) --  IMMUNOVANT, INC. (NASDAQ: IMVT), A CLINICAL-STAGE IMMU...
Více zde

IMMUNOVANT TO PRESENT AT UPCOMING INVESTOR CONFERENCES

13-11-2023
NEW YORK, NOV. 13, 2023 (GLOBE NEWSWIRE) -- IMMUNOVANT, INC. (NASDAQ: IMVT), A CLINICAL-STAGE IMMUNO...
Více zde

close

Datum Typ Otevřít EDGAR Stáhnout dokument
2026-02-06 00:00:008-KStáhnout
2026-02-06 00:00:0010-QStáhnout
2025-12-12 00:00:008-KStáhnout
2025-12-11 00:00:008-KStáhnout
2025-11-21 00:00:008-KStáhnout
2025-11-10 00:00:008-KStáhnout
2025-11-10 00:00:0010-QStáhnout
2025-09-03 01:00:008-KStáhnout
2025-09-03 00:00:008-KStáhnout
2025-08-28 01:00:008-KStáhnout
2025-08-28 00:00:008-KStáhnout
2025-08-11 01:00:008-KStáhnout
2025-08-11 01:00:0010-QStáhnout
2025-08-11 00:00:008-KStáhnout
2025-08-11 00:00:0010-QStáhnout
2025-07-29 01:00:008-KStáhnout
2025-07-29 00:00:008-KStáhnout
2025-05-29 01:00:008-KStáhnout
2025-05-29 01:00:0010-KStáhnout
2025-05-29 00:00:008-KStáhnout
2025-05-29 00:00:0010-KStáhnout
2025-04-21 01:00:008-KStáhnout
2025-04-21 00:00:008-KStáhnout
2025-03-19 00:00:008-KStáhnout
2025-03-18 23:00:008-KStáhnout
2025-02-06 00:00:008-KStáhnout
2025-02-06 00:00:0010-QStáhnout
2025-02-05 23:00:008-KStáhnout
2025-02-05 23:00:0010-QStáhnout
2025-01-24 00:00:008-KStáhnout
2025-01-23 23:00:008-KStáhnout
2025-01-14 00:00:008-KStáhnout
2025-01-13 23:00:008-KStáhnout
2025-01-13 00:00:008-KStáhnout
2025-01-12 23:00:008-KStáhnout
2024-11-07 00:00:008-KStáhnout
2024-11-07 00:00:0010-QStáhnout
2024-11-06 23:00:008-KStáhnout
2024-11-06 23:00:0010-QStáhnout
2024-09-09 01:00:008-KStáhnout
2024-09-09 00:00:008-KStáhnout
2024-08-13 01:00:008-KStáhnout
2024-08-13 00:00:008-KStáhnout
2024-08-06 01:00:008-KStáhnout
2024-08-06 01:00:0010-QStáhnout
2024-08-06 00:00:008-KStáhnout
2024-08-06 00:00:0010-QStáhnout
2024-05-29 01:00:008-KStáhnout
2024-05-29 01:00:0010-KStáhnout
2024-05-29 00:00:008-KStáhnout
2024-05-29 00:00:0010-KStáhnout
2024-02-12 00:00:008-KStáhnout
2024-02-12 00:00:0010-QStáhnout
2024-02-11 23:00:008-KStáhnout
2024-02-11 23:00:0010-QStáhnout
2024-01-09 00:00:008-KStáhnout
2024-01-08 23:00:008-KStáhnout
2023-12-20 00:00:008-KStáhnout
2023-12-19 23:00:008-KStáhnout
2023-11-28 00:00:008-KStáhnout
2023-11-27 23:00:008-KStáhnout
2023-11-09 00:00:008-KStáhnout
2023-11-09 00:00:0010-QStáhnout
2023-11-08 23:00:008-KStáhnout
2023-11-08 23:00:0010-QStáhnout
2023-09-28 01:00:008-KStáhnout
2023-09-28 00:00:008-KStáhnout
2023-09-26 01:00:008-KStáhnout
2023-09-26 00:00:008-KStáhnout
2023-08-23 01:00:008-KStáhnout
2023-08-23 00:00:008-KStáhnout
2023-08-10 01:00:008-KStáhnout
2023-08-10 01:00:0010-QStáhnout
2023-08-10 00:00:008-KStáhnout
2023-08-10 00:00:0010-QStáhnout
2023-05-22 01:00:008-KStáhnout
2023-05-22 01:00:0010-KStáhnout
2023-05-22 00:00:008-KStáhnout
2023-05-22 00:00:0010-KStáhnout
2023-03-27 01:00:008-KStáhnout
2023-03-27 00:00:008-KStáhnout
2023-02-03 00:00:008-KStáhnout
2023-02-03 00:00:0010-QStáhnout
2023-02-02 23:00:008-KStáhnout
2023-02-02 23:00:0010-QStáhnout
2023-01-09 00:00:008-KStáhnout
2023-01-08 23:00:008-KStáhnout
2022-12-08 00:00:008-KStáhnout
2022-12-07 23:00:008-KStáhnout
2022-11-04 00:00:008-KStáhnout
2022-11-04 00:00:0010-QStáhnout
2022-11-03 23:00:008-KStáhnout
2022-11-03 23:00:0010-QStáhnout
2022-10-04 01:00:008-KStáhnout
2022-10-04 00:00:008-KStáhnout
2022-09-28 01:00:008-KStáhnout
2022-09-28 00:00:008-KStáhnout
2022-09-07 01:00:008-KStáhnout
2022-09-07 00:00:008-KStáhnout
2022-08-19 01:00:008-KStáhnout
2022-08-19 00:00:008-KStáhnout
2022-08-05 01:00:008-KStáhnout
2022-08-05 01:00:0010-QStáhnout
2022-08-05 00:00:008-KStáhnout
2022-08-05 00:00:0010-QStáhnout
2022-06-08 01:00:008-KStáhnout
2022-06-08 01:00:0010-KStáhnout
2022-06-08 00:00:008-KStáhnout
2022-06-08 00:00:0010-KStáhnout
2022-03-30 01:00:008-KStáhnout
2022-03-30 00:00:008-KStáhnout
2022-02-04 00:00:008-KStáhnout
2022-02-04 00:00:0010-QStáhnout
2022-02-03 23:00:008-KStáhnout
2022-02-03 23:00:0010-QStáhnout
2022-01-07 00:00:008-KStáhnout
2022-01-06 23:00:008-KStáhnout
2022-01-05 00:00:008-KStáhnout
2022-01-04 23:00:008-KStáhnout
2021-12-30 00:00:008-KStáhnout
2021-12-29 23:00:008-KStáhnout
2021-11-23 00:00:008-KStáhnout
2021-11-22 23:00:008-KStáhnout
2021-11-17 00:00:008-KStáhnout
2021-11-16 23:00:008-KStáhnout
2021-11-05 00:00:008-KStáhnout
2021-11-05 00:00:0010-QStáhnout
2021-11-04 23:00:008-KStáhnout
2021-11-04 23:00:0010-QStáhnout
2021-09-27 01:00:008-KStáhnout
2021-09-27 00:00:008-KStáhnout
2021-09-15 01:00:008-KStáhnout
2021-09-15 00:00:008-KStáhnout
2021-08-09 01:00:008-KStáhnout
2021-08-09 01:00:0010-QStáhnout
2021-08-09 00:00:008-KStáhnout
2021-08-09 00:00:0010-QStáhnout
2021-08-02 01:00:008-KStáhnout
2021-08-02 00:00:008-KStáhnout
2021-07-13 01:00:008-KStáhnout
2021-07-13 00:00:008-KStáhnout
2021-06-01 01:00:008-KStáhnout
2021-06-01 01:00:0010-KStáhnout
2021-06-01 00:00:008-KStáhnout
2021-06-01 00:00:0010-KStáhnout
2021-02-16 00:00:008-KStáhnout
2021-02-16 00:00:0010-QStáhnout
2021-02-15 23:00:008-KStáhnout
2021-02-15 23:00:0010-QStáhnout
2021-02-02 00:00:008-KStáhnout
2021-02-01 23:00:008-KStáhnout
2020-11-12 00:00:008-KStáhnout
2020-11-12 00:00:0010-QStáhnout
2020-11-11 23:00:008-KStáhnout
2020-11-11 23:00:0010-QStáhnout
2020-09-18 01:00:008-KStáhnout
2020-09-18 00:00:008-KStáhnout
2020-08-25 01:00:008-KStáhnout
2020-08-25 00:00:008-KStáhnout
2020-08-21 01:00:008-KStáhnout
2020-08-21 00:00:008-KStáhnout
2020-08-12 01:00:008-KStáhnout
2020-08-12 01:00:0010-QStáhnout
2020-08-12 00:00:008-KStáhnout
2020-08-12 00:00:0010-QStáhnout
2020-06-29 01:00:008-KStáhnout
2020-06-29 01:00:0010-KStáhnout
2020-06-29 00:00:008-KStáhnout
2020-06-29 00:00:0010-KStáhnout
2020-05-14 01:00:008-KStáhnout
2020-05-14 00:00:008-KStáhnout
2020-03-30 01:00:008-KStáhnout
2020-03-30 00:00:008-KStáhnout
2020-02-19 00:00:008-KStáhnout
2020-02-18 23:00:008-KStáhnout
2020-02-14 00:00:008-KStáhnout
2020-02-14 00:00:0010-QStáhnout
2020-02-13 23:00:008-KStáhnout
2020-02-13 23:00:0010-QStáhnout
2019-12-20 00:00:008-KStáhnout
2019-12-19 23:00:008-KStáhnout
2019-12-17 00:00:008-KStáhnout
2019-12-16 23:00:008-KStáhnout
2019-12-02 00:00:008-KStáhnout
2019-12-01 23:00:008-KStáhnout
2019-11-25 00:00:008-KStáhnout
2019-11-24 23:00:008-KStáhnout
2019-11-14 00:00:008-KStáhnout
2019-11-13 23:00:008-KStáhnout
2019-11-13 00:00:0010-QStáhnout
2019-11-12 23:00:0010-QStáhnout
2019-11-12 00:00:008-KStáhnout
2019-11-11 23:00:008-KStáhnout
2019-10-29 00:00:008-KStáhnout
2019-10-28 23:00:008-KStáhnout
2019-10-15 01:00:008-KStáhnout
2019-10-15 00:00:008-KStáhnout
2019-10-08 01:00:008-KStáhnout
2019-10-08 00:00:008-KStáhnout
2019-10-04 01:00:008-KStáhnout
2019-10-04 00:00:008-KStáhnout
2019-10-02 01:00:008-KStáhnout
2019-10-02 00:00:008-KStáhnout
2019-08-26 01:00:008-KStáhnout
2019-08-26 00:00:008-KStáhnout
2019-08-12 01:00:0010-QStáhnout
2019-08-12 00:00:0010-QStáhnout
2019-06-12 01:00:0010-QStáhnout
2019-06-12 00:00:0010-QStáhnout
2019-05-15 01:00:008-KStáhnout
2019-05-15 00:00:008-KStáhnout
preloader